Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate + Ganciclovir/Valganciclovir for CMV Infection in Solid Organ Transplant Recipients
NCT06853184Phase 2Recruiting
- Sponsor
- AMIVAS
- Start
- Aug 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of artesunate in cytomegalovirus infection (CMV) (3 arms), sponsored by AMIVAS. Primary endpoint: Reduction of cytomegalovirus (CMV) DNAemia at 28 days. Started Aug 2025; status: recruiting.
02
Drugs
artesunate
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06853184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06853184.